Investment Highlights

With new and unique technologies and active substances, the biotech company MOLOGEN is one of the pioneers in the field of immunotherapy. Alongside a focus on immuno-oncology, MOLOGEN also develops immunotherapies for the treatment of infectious diseases.

What sets us apart:

  • Biotech company developing ground-breaking immunotherapies
  • Lead product lefitolimod (MGN1703): potential blockbuster candidate
  • Targeting indications with high unmet medical needs: Cancer and HIV
  • Attractive for partnering/licensing: Advanced, close-to-market product candidate with long-term exclusivity and promising next generation successor molecules

- Clinically relevant subgroups benefit from the treatment with lefitolimod in this study - Results are indicative for the further development of lefitolimod in SCLC [more]

Annual Report 2016
Download PDF

 

 

March 22, 2017
Full Year Report 2016

 

Show complete Corporate Calendar.

 

May 8, 2017 - May 10, 2017

8. DVFA Spring Conference, Frankfurt 

 

March 20, 2017 - March 22, 2017

ITOC 4th Immunotherapy of Cancer Conference, Prague, CZ


March 19, 2017 - March 23, 2017

Keystone Symposium, Whistler, Canada


Show complete calendar.

 

 

 

Positive subgroup results IMPULSE study

Press Release
Presentation

Share Price

Contact:

Claudia Nickolaus
Head of Investor Relations & Corporate Communications
Phone: +49 - 30 - 84 17 88 - 38
Fax: +49 - 30 - 84 17 88 - 50
investor@mologen.com

Distribution list

If you would like to receive our press releases, please click here.